News|Articles|July 10, 2026

Accelerating Complex Drug Development With Precision Micronization (July 2026)

Author(s)Catalent

Catalent’s micronization services help innovators overcome the toughest drug development challenges. Our high-containment facilities and expert scientists deliver consistent particle size reduction, high API recovery, and audit-ready processes to support early-phase clinical programs. Whether your project requires potent API handling, rapid turnaround, or extended analytical verification, Catalent combines speed, precision, and compliance to keep your milestones on track. Gain insights into real-world case studies that demonstrate how our structured, transparent approach ensures reliable delivery while protecting your valuable APIs. Discover why leading pharmaceutical and biotech companies choose Catalent as their trusted CDMO partner for micronization.


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.